Taiwan Biotech Leaders Drive Global Expansion with AI and Advanced Production
At JPM 2026 two Taiwanese firms signaled a strategic upgrade of the island’s biopharma profile. Bora Pharmaceuticals and EirGenix presented moves that shift Taiwan from a capacity provider to a technology-forward partner for global drugmakers, highlighting AI-driven manufacturing, US onshoring and next generation production technologies.
Bora Pharmaceuticals: US Growth and AI Manufacturing
Bora outlined a dual-engine strategy combining domestic innovation with accelerated US capacity buildout. The company has pursued US M&A and partnerships including assets such as Upsher-Smith and capacity acquired from Emergent BioSolutions to establish local manufacturing footprint. Parallel to expansion, Bora formed an AI committee tasked with developing proprietary models to predict process performance, reduce batch variability and shorten qualification cycles. Their commercial focus is shifting toward higher-complexity Rx assets, including products like vigabatrin, supporting margin improvement and differentiated global sales.
EirGenix: Continuous Manufacturing and Biosimilar Alliances
EirGenix showcased continuous manufacturing at JPM, a move aimed at cutting cost per dose and improving throughput. Over the past two years the company built a digitized knowledge management system that now integrates AI analytics to assess process risk, accelerate process development and streamline regulatory filings. EirGenix also reinforced its global commercialization plan through licensing deals with Sandoz for biosimilars EG12014 and EG1206A, positioning Taiwan-made biologics for broader international markets.
Taiwan’s Strategic Shift in Global Biopharma
Together these announcements indicate a qualitative shift: Taiwanese firms are combining onshored manufacturing capacity with advanced production technologies and AI tools to compete on value rather than cost alone. For investors and partners, Taiwan is emerging as a hub for AI-powered biomanufacturing and biosimilar development capable of meeting stringent global standards.
